Technology

Mersana has developed highly differentiated and innovative antibody-drug conjugate (ADC) platforms, with both cytotoxic and immunostimulatory payloads, that allow for customization and optimization of ADCs for a given target and indication.  As a result, we are developing ADCs designed to overcome the limitations of first-generation platforms and improve efficacy and tolerability in order to address the unmet medical needs of people living with cancer.

Pipeline

We have leveraged our proprietary technology platforms to build a pipeline of ADCs with the potential to meaningfully improve the lives of people living with cancer. We are pursuing a multi-pronged strategy for cancer treatment that includes both cytotoxic and immunostimulatory ADC approaches.